

Brian A Gordon

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8190805/brian-a-gordon-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

185
papers

4,585
citations

34
h-index

67
g-index

204
ext. papers

6,294
ext. citations

7
avg, IF

5.43
L-index

#	Paper	IF	Citations
185	Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease. <i>Science Translational Medicine</i> , 2016 , 8, 338ra66	17.5	418
184	Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease. <i>Nature Medicine</i> , 2019 , 25, 277-283	50.5	375
183	Span, CRUNCH, and beyond: working memory capacity and the aging brain. <i>Journal of Cognitive Neuroscience</i> , 2010 , 22, 655-69	3.1	272
182	High-precision plasma Aβ amyloid 42/40 predicts current and future brain amyloidosis. <i>Neurology</i> , 2019 , 93, e1647-e1659	6.5	245
181	Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study. <i>Lancet Neurology</i> , 2018 , 17, 241-250	24.1	224
180	Tau Kinetics in Neurons and the Human Central Nervous System. <i>Neuron</i> , 2018 , 97, 1284-1298.e7	13.9	208
179	A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease. <i>Nature Medicine</i> , 2020 , 26, 398-407	50.5	160
178	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. <i>World Journal of Biological Psychiatry</i> , 2018 , 19, 244-328	3.8	148
177	Neurovascular coupling in normal aging: a combined optical, ERP and fMRI study. <i>NeuroImage</i> , 2014 , 85 Pt 1, 592-607	7.9	145
176	Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease. <i>Neurology</i> , 2018 , 91, e1295-e1306	6.5	129
175	The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging. <i>Brain</i> , 2016 , 139, 2249-60	11.2	125
174	Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging. <i>Alzheimer's and Dementia</i> , 2018 , 14, 1460-1469	1.2	120
173	Assessment of Racial Disparities in Biomarkers for Alzheimer Disease. <i>JAMA Neurology</i> , 2019 , 76, 264-273.2	37.2	117
172	Influence of tau PET, amyloid PET, and hippocampal volume on cognition in Alzheimer disease. <i>Neurology</i> , 2018 , 91, e859-e866	6.5	116
171	Effects of measurement method, wavelength, and source-detector distance on the fast optical signal. <i>NeuroImage</i> , 2006 , 32, 1576-90	7.9	103
170	Neuroanatomical correlates of aging, cardiopulmonary fitness level, and education. <i>Psychophysiology</i> , 2008 , 45, 825-38	4.1	97
169	AV-1451 PET imaging of tau pathology in preclinical Alzheimer disease: Defining a summary measure. <i>NeuroImage</i> , 2017 , 161, 171-178	7.9	76

168	Structural correlates of prospective memory. <i>Neuropsychologia</i> , 2011 , 49, 3795-800	3.2	71
167	Tau PET in autosomal dominant Alzheimer's disease: relationship with cognition, dementia and other biomarkers. <i>Brain</i> , 2019 , 142, 1063-1076	11.2	71
166	Imaging and cerebrospinal fluid biomarkers in early preclinical alzheimer disease. <i>Annals of Neurology</i> , 2016 , 80, 379-87	9.4	65
165	NIA-AA staging of preclinical Alzheimer disease: discordance and concordance of CSF and imaging biomarkers. <i>Neurobiology of Aging</i> , 2016 , 44, 1-8	5.6	65
164	Longitudinal β Amyloid Deposition and Hippocampal Volume in Preclinical Alzheimer Disease and Suspected Non-Alzheimer Disease Pathophysiology. <i>JAMA Neurology</i> , 2016 , 73, 1192-1200	17.2	63
163	Plasma neurofilament light chain in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional and longitudinal cohort study. <i>Lancet Neurology</i> , 2020 , 19, 513-521	24.1	53
162	Longitudinal brain imaging in preclinical Alzheimer disease: impact of APOE ϵ genotype. <i>Brain</i> , 2018 , 141, 1828-1839	11.2	53
161	A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. <i>Nature Medicine</i> , 2021 , 27, 1187-1196	50.5	51
160	Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studies. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019 , 11, 180-190	5.2	46
159	Loss of white matter integrity reflects tau accumulation in Alzheimer disease defined regions. <i>Neurology</i> , 2018 , 91, e313-e318	6.5	43
158	Prefrontal gray matter volume mediates age effects on memory strategies. <i>NeuroImage</i> , 2014 , 90, 326-349	3.9	41
157	Aerobic glycolysis and tau deposition in preclinical Alzheimer's disease. <i>Neurobiology of Aging</i> , 2018 , 67, 95-98	5.6	40
156	Tau-PET Binding Distinguishes Patients With Early-stage Posterior Cortical Atrophy From Amnesic Alzheimer Disease Dementia. <i>Alzheimer Disease and Associated Disorders</i> , 2017 , 31, 87-93	2.5	37
155	Utilizing the Centiloid scale in cross-sectional and longitudinal PiB PET studies. <i>NeuroImage: Clinical</i> , 2018 , 19, 406-416	5.3	37
154	Cross-sectional and longitudinal atrophy is preferentially associated with tau rather than amyloid β positron emission tomography pathology. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018 , 10, 245-252	5.2	34
153	The BDNF SNP modulates the association between beta-amyloid and hippocampal disconnection in Alzheimer's disease. <i>Molecular Psychiatry</i> , 2021 , 26, 614-628	15.1	34
152	The effects of white matter hyperintensities and amyloid deposition on Alzheimer dementia. <i>NeuroImage: Clinical</i> , 2015 , 8, 246-52	5.3	32
151	Task-evoked fMRI changes in attention networks are associated with preclinical Alzheimer's disease biomarkers. <i>Neurobiology of Aging</i> , 2015 , 36, 1771-9	5.6	30

150	Effect of apolipoprotein E4 on clinical, neuroimaging, and biomarker measures in noncarrier participants in the Dominantly Inherited Alzheimer Network. <i>Neurobiology of Aging</i> , 2019 , 75, 42-50	5.6	26
149	Widespread distribution of tauopathy in preclinical Alzheimer's disease. <i>Neurobiology of Aging</i> , 2018 , 72, 177-185	5.6	26
148	Cerebral amyloidosis associated with cognitive decline in autosomal dominant Alzheimer disease. <i>Neurology</i> , 2015 , 85, 790-8	6.5	23
147	Effects of aging and Alzheimer's disease along the longitudinal axis of the hippocampus. <i>Journal of Alzheimer's Disease</i> , 2013 , 37, 41-50	4.3	23
146	A diffusion model analysis of episodic recognition in preclinical individuals with a family history for Alzheimer's disease: The adult children study. <i>Neuropsychology</i> , 2016 , 30, 225-38	3.8	23
145	Comparing Aging and Fitness Effects on Brain Anatomy. <i>Frontiers in Human Neuroscience</i> , 2016 , 10, 286	3.3	22
144	In vivo [F]-AV-1451 tau-PET imaging in sporadic Creutzfeldt-Jakob disease. <i>Neurology</i> , 2018 , 90, e896-e906	6.5	20
143	Predicting sporadic Alzheimer's disease progression via inherited Alzheimer's disease-informed machine-learning. <i>Alzheimer's and Dementia</i> , 2020 , 16, 501-511	1.2	20
142	Frequency analysis of the visual steady-state response measured with the fast optical signal in younger and older adults. <i>Biological Psychology</i> , 2010 , 85, 79-89	3.2	18
141	Neurofilaments in disease: what do we know?. <i>Current Opinion in Neurobiology</i> , 2020 , 61, 105-115	7.6	17
140	Quantification of white matter cellularity and damage in preclinical and early symptomatic Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2019 , 22, 101767	5.3	16
139	Discovery and validation of autosomal dominant Alzheimer's disease mutations. <i>Alzheimer's Research and Therapy</i> , 2018 , 10, 67	9	16
138	Serum neurofilament light chain levels are associated with white matter integrity in autosomal dominant Alzheimer's disease. <i>Neurobiology of Disease</i> , 2020 , 142, 104960	7.5	15
137	Association of Longitudinal Changes in Cerebrospinal Fluid Total Tau and Phosphorylated Tau 181 and Brain Atrophy With Disease Progression in Patients With Alzheimer Disease. <i>JAMA Network Open</i> , 2019 , 2, e1917126	10.4	15
136	Evaluating the Sensitivity of Resting-State BOLD Variability to Age and Cognition after Controlling for Motion and Cardiovascular Influences: A Network-Based Approach. <i>Cerebral Cortex</i> , 2020 , 30, 5686-5701	5.1	14
135	Evidence for a detrimental relationship between hypertension history, prospective memory, and prefrontal cortex white matter in cognitively normal older adults. <i>Cognitive, Affective and Behavioral Neuroscience</i> , 2013 , 13, 405-16	3.5	14
134	Clinical, imaging, pathological, and biochemical characterization of a novel presenilin 1 mutation (N135Y) causing Alzheimer's disease. <i>Neurobiology of Aging</i> , 2017 , 49, 216.e7-216.e13	5.6	13
133	Segregation of functional networks is associated with cognitive resilience in Alzheimer's disease. <i>Brain</i> , 2021 , 144, 2176-2185	11.2	13

132	Amyloid and Tau Pathology Associations With Personality Traits, Neuropsychiatric Symptoms, and Cognitive Lifestyle in the Preclinical Phases of Sporadic and Autosomal Dominant Alzheimer's Disease. <i>Biological Psychiatry</i> , 2021 , 89, 776-785	7.9	13
131	Socioeconomic Status Mediates Racial Differences Seen Using the AT(N) Framework. <i>Annals of Neurology</i> , 2021 , 89, 254-265	9.4	13
130	Predicting dysfunctional age-related task activations from resting-state network alterations. <i>NeuroImage</i> , 2020 , 221, 117167	7.9	12
129	Association between personality and tau-PET binding in cognitively normal older adults. <i>Brain Imaging and Behavior</i> , 2020 , 14, 2122-2131	4.1	11
128	Utility of perfusion PET measures to assess neuronal injury in Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018 , 10, 669-677	5.2	11
127	Higher Body Mass Index Is Associated with Lower Cortical Amyloid- β Burden in Cognitively Normal Individuals in Late-Life. <i>Journal of Alzheimer's Disease</i> , 2019 , 69, 817-827	4.3	9
126	Spread of activation and deactivation in the brain: does age matter?. <i>Frontiers in Aging Neuroscience</i> , 2014 , 6, 288	5.3	9
125	Sex-related Differences in Tau Positron Emission Tomography (PET) and the Effects of Hormone Therapy (HT). <i>Alzheimer Disease and Associated Disorders</i> , 2021 , 35, 164-168	2.5	9
124	Comparing amyloid- β plaque burden with antemortem PiB PET in autosomal dominant and late-onset Alzheimer disease. <i>Acta Neuropathologica</i> , 2021 , 142, 689-706	14.3	8
123	Select Atrophied Regions in Alzheimer disease (SARA): An improved volumetric model for identifying Alzheimer disease dementia. <i>NeuroImage: Clinical</i> , 2020 , 26, 102248	5.3	7
122	Left caudal middle frontal gray matter volume mediates the effect of age on self-initiated elaborative encoding strategies. <i>Neuropsychologia</i> , 2017 , 106, 341-349	3.2	7
121	Temporal Correlation of CSF and Neuroimaging in the Amyloid-Tau-Neurodegeneration Model of Alzheimer Disease. <i>Neurology</i> , 2021 , 97, e76-e87	6.5	7
120	Single-subject grey matter network trajectories over the disease course of autosomal dominant Alzheimer's disease. <i>Brain Communications</i> , 2020 , 2, fcaa102	4.5	6
119	Evaluating resting-state BOLD variability in relation to biomarkers of preclinical Alzheimer's disease. <i>Neurobiology of Aging</i> , 2020 , 96, 233-245	5.6	6
118	Simultaneously evaluating the effect of baseline levels and longitudinal changes in disease biomarkers on cognition in dominantly inherited Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2018 , 4, 669-676	6	6
117	Accelerated functional brain aging in pre-clinical familial Alzheimer's disease. <i>Nature Communications</i> , 2021 , 12, 5346	17.4	6
116	Variant-dependent heterogeneity in amyloid β burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study.. <i>Lancet Neurology</i> , 2022 , 21, 140-152	24.1	5
115	Resting-State Functional Connectivity Disruption as a Pathological Biomarker in Autosomal Dominant Alzheimer Disease. <i>Brain Connectivity</i> , 2021 , 11, 239-249	2.7	5

114	Predicting Symptom Onset in Sporadic Alzheimer Disease With Amyloid PET. <i>Neurology</i> , 2021 , 97, e18236-e18345	6.5	5
113	Modeling autosomal dominant Alzheimer's disease with machine learning. <i>Alzheimer's and Dementia</i> , 2021 , 17, 1005-1016	1.2	5
112	Ante- and postmortem tau in autosomal dominant and late-onset Alzheimer's disease. <i>Annals of Clinical and Translational Neurology</i> , 2020 , 7, 2475-2480	5.3	4
111	Neurofilament Light Predicts Decline in Attention but Not Episodic Memory in Preclinical Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020 , 74, 1119-1129	4.3	4
110	Regional variability in Alzheimer's disease biomarkers. <i>Future Neurology</i> , 2014 , 9, 131-134	1.5	4
109	Tau and Amyloid Positron Emission Tomography Imaging Predict Driving Performance Among Older Adults with and without Preclinical Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018 , 61, 509-513	4.3	4
108	Comparing cortical signatures of atrophy between late-onset and autosomal dominant Alzheimer disease. <i>NeuroImage: Clinical</i> , 2020 , 28, 102491	5.3	4
107	Longitudinal Accumulation of Cerebral Microhemorrhages in Dominantly Inherited Alzheimer Disease. <i>Neurology</i> , 2021 , 96, e1632-e1645	6.5	4
106	Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer's disease: a longitudinal observational study.. <i>Lancet Neurology, The</i> , 2022 , 21, 329-341	24.1	4
105	Effect of Race on Prediction of Brain Amyloidosis by Plasma A β 2/A β 0, Phosphorylated Tau, and Neurofilament Ligh.. <i>Neurology</i> , 2022 ,	6.5	4
104	Overview of dominantly inherited AD and top-line DIAN-TU results of solanezumab and gantenerumab. <i>Alzheimer's and Dementia</i> , 2020 , 16, e041129	1.2	3
103	Sharper in the morning: Cognitive time of day effects revealed with high-frequency smartphone testing.. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2022 , 1-13	2.1	3
102	Functional brain age prediction suggests accelerated aging in preclinical familial Alzheimer's disease, irrespective of fibrillar amyloid-beta pathology		3
101	P4-108: RESTING-STATE FUNCTIONAL CONNECTIVITY IS ASSOCIATED WITH PATHOLOGICAL BIOMARKERS IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE 2018 , 14, P1480-P1480		3
100	Tau positron emission tomography imaging in C9orf72 repeat expansion carriers. <i>European Journal of Neurology</i> , 2019 , 26, 1235-1239	6	2
99	Solanezumab in-depth outcomes. <i>Alzheimer's and Dementia</i> , 2020 , 16, e038028	1.2	2
98	Undetected Neurodegenerative Disease Biases Estimates of Cognitive Change in Older Adults. <i>Psychological Science</i> , 2021 , 32, 849-860	7.9	2
97	Evaluating Cognitive Relationships with Resting-State and Task-driven Blood Oxygen Level-Dependent Variability. <i>Journal of Cognitive Neuroscience</i> , 2021 , 33, 279-302	3.1	2

96	Cerebrospinal fluid A β 2 moderates the relationship between brain functional network dynamics and cognitive intraindividual variability. <i>Neurobiology of Aging</i> , 2021 , 98, 116-123	5.6	2
95	Flortaucipir (tau) PET in LGI1 antibody encephalitis. <i>Annals of Clinical and Translational Neurology</i> , 2021 , 8, 491-497	5.3	2
94	Elevated tau PET signal depends on abnormal amyloid levels and is uncommon in unimpaired individuals. <i>Brain</i> , 2019 , 142, 2903-2904	11.2	1
93	Author response: In vivo [F]-AV-1451 tau-PET imaging in sporadic Creutzfeldt-Jakob disease. <i>Neurology</i> , 2019 , 92, 150	6.5	1
92	Gantenerumab in-depth outcomes. <i>Alzheimer's and Dementia</i> , 2020 , 16, e038049	1.2	1
91	Socioeconomic status mediating sex and racial differences using the AT(N) framework. <i>Alzheimer's and Dementia</i> , 2020 , 16, e041229	1.2	1
90	Brain network dysfunction associated with blood neurofilament light chain in autosomal dominant Alzheimer disease. <i>Alzheimer's and Dementia</i> , 2020 , 16, e041586	1.2	1
89	Measures of metabolism provide insights into hippocampal sclerosis. <i>Brain</i> , 2018 , 141, 946-948	11.2	1
88	IC-P-164: Patterns of tau binding in T807-PET imaging 2015 , 11, P110-P110		1
87	Beta-amyloid moderates the relationship between cortical thickness and attentional control in middle- and older-aged adults.. <i>Neurobiology of Aging</i> , 2022 , 112, 181-190	5.6	1
86	Cerebrospinal fluid neurofilament light chain is a marker of aging and white matter damage.. <i>Neurobiology of Disease</i> , 2022 , 105662	7.5	1
85	The Effects of Aging and Physical Fitness on Working Memory Capacity. <i>Korean Journal of Cognitive and Biological Psychology</i> , 2012 , 24, 107-126	0.3	1
84	Spatiotemporal relationship between subthreshold amyloid accumulation and aerobic glycolysis in the human brain. <i>Neurobiology of Aging</i> , 2020 , 96, 165-175	5.6	1
83	P3-251: SERUM NEUROFILAMENT LIGHT CHAIN LEVELS ARE ASSOCIATED WITH CSF NEUROFILAMENT LIGHT CHAIN, COGNITIVE STATUS, AND DISEASE PROGRESSION IN AUTOSOMAL DOMINANT AD 2018 , 14, P1170-P1170		1
82	Regional age-related atrophy after screening for preclinical alzheimer disease. <i>Neurobiology of Aging</i> , 2021 , 109, 43-51	5.6	1
81	Neuroimaging within the Dominantly Inherited Alzheimer's Network (DIAN): PET and MRI		1
80	Sharper in the morning: Cognitive sundowning revealed with high-frequency smartphone testing. <i>Alzheimer's and Dementia</i> , 2021 , 17,	1.2	1
79	Predicting brain age from functional connectivity in symptomatic and preclinical Alzheimer disease.. <i>NeuroImage</i> , 2022 , 119228	7.9	1

78	Mass spectrometry measures of plasma A β tau and P-tau isoforms relationship to amyloid PET, tau PET, and clinical stage of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020 , 16, e037518	1.2	○
77	A comparison of the Montreal Cognitive Assessment and standard cognitive measures in the National Alzheimer's Coordinating Center and Knight Alzheimer's Disease Research Center cohorts. <i>Alzheimer's and Dementia</i> , 2020 , 16, e046780	1.2	○
76	Leveraging molecular biomarkers to make the common diagnosis in the uncommon patient. <i>Journal of Neuroimmunology</i> , 2021 , 352, 577474	3.5	○
75	IC-P-204: THE RELATIONSHIP BETWEEN TAU PET AND OTHER AD BIOMARKERS IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE 2018 , 14, P167-P168		○
74	CSF Tau phosphorylation at Thr205 is associated with loss of white matter integrity in autosomal dominant Alzheimer's disease.. <i>Neurobiology of Disease</i> , 2022 , 105714	7.5	○
73	Plasma Neurofilament Light Chain Levels Are Elevated in Children and Young Adults With Wolfram Syndrome.. <i>Frontiers in Neuroscience</i> , 2022 , 16, 795317	5.1	○
72	Association between cerebrospinal fluid neurofilament light chain and markers of neurofibrillary pathophysiology: Findings from the Knight Alzheimer Disease Research Center. <i>Alzheimer's and Dementia</i> , 2020 , 16, e037136	1.2	
71	Global system segregation enhances reserve in normal aging and Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020 , 16, e037930	1.2	
70	Tau kinetics in Alzheimer disease and primary tauopathies. <i>Alzheimer's and Dementia</i> , 2020 , 16, e039109	1.2	
69	Tauopathy in autosomal dominant and late-onset Alzheimer disease. <i>Alzheimer's and Dementia</i> , 2020 , 16, e041683	1.2	
68	APOE4 status influences the amyloid and tau relationship. <i>Alzheimer's and Dementia</i> , 2020 , 16, e042093	1.2	
67	Socioeconomic status mediates racial differences seen using the AT(N) framework. <i>Alzheimer's and Dementia</i> , 2020 , 16, e043216	1.2	
66	Head-to-head comparison of [18F]MK-6240 and [18F]flortaucipir (AV-1451) in autosomal dominant Alzheimer disease. <i>Alzheimer's and Dementia</i> , 2020 , 16, e044688	1.2	
65	Default mode network dedifferentiation predicts cognitive performance in Alzheimer disease. <i>Alzheimer's and Dementia</i> , 2020 , 16, e044790	1.2	
64	Cross-modal associations between traditional and emerging CSF biomarkers and grey matter network disruption in autosomal dominant Alzheimer disease. <i>Alzheimer's and Dementia</i> , 2020 , 16, e045905	1.2	
63	Associations of brain connectivity with disease progression and cognitive dysfunction in autosomal-dominant Alzheimer disease depend on imaging modality. <i>Alzheimer's and Dementia</i> , 2020 , 16, e045942	1.2	
62	Evaluation of 18F-MK-6240 and 18F-AV-1451 tau PET tracers in Alzheimer disease. <i>Alzheimer's and Dementia</i> , 2020 , 16, e046124	1.2	
61	Neurofilament light is a non-specific marker of aging and white matter integrity. <i>Alzheimer's and Dementia</i> , 2020 , 16, e046169	1.2	

- 60 Vasogenic edema in the frontostriatal tract and the anterior limb of the internal capsule predict cognitive decline in Alzheimer disease. *Alzheimer's and Dementia*, **2020**, 16, e046183 1.2
- 59 A time-embedding network model captures dynamic longitudinal pathology changes in a dominantly inherited Alzheimer disease population. *Alzheimer's and Dementia*, **2020**, 16, e046335 1.2
- 58 Investigating whether fractional anisotropy is associated with reduced reaction time cost on an attentional control task. *Alzheimer's and Dementia*, **2020**, 16, e046462 1.2
- 57 IC-P-179: TAU Imaging Relationships With Amyloid B Imaging, CSF TAU/AB42, and Cognition in Alzheimer's Disease **2016**, 12, P130-P131
- 56 IC-P-166: TAU PET IMAGING IN LGI1 ENCEPHALITIS: DECIPHERING THE CONTRIBUTORS TO COGNITIVE IMPAIRMENT IN AUTOIMMUNE ENCEPHALITIS **2019**, 15, P131-P131
- 55 IC-P-051: Amyloid load increase and cerebral microbleed prevalence differ as a function of the position of the mutation within the PSEN1 coding sequence **2015**, 11, P41-P41
- 54 O1-01-01: Comparison of nia-aa preclinical Alzheimer's disease staging with CSF and neuroimaging biomarkers **2015**, 11, P122-P123
- 53 P3-175: The ilp: A new tool for evaluating preclinical Alzheimer's disease using volumetric MRI in a single participant **2015**, 11, P697-P697
- 52 [IC-P-057]: CLINICAL RISK RELATED TO CEREBRAL MICROHEMORRHAGES IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE: LONGITUDINAL RESULTS FROM THE DIAN STUDY **2017**, 13, P47-P47
- 51 [P2B72]: UTILITY OF PERFUSION PET MODELS AS MEASURES OF NEURODEGENERATION IN AN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE POPULATION: REPORT FROM THE DIAN STUDY **2017**, 13, P768-P769
- 50 [P1D08]: RELATIONSHIP BETWEEN TAU POSITRON EMISSION TOMOGRAPHY WITH [18F]-AV-1451 AND LONGITUDINAL CORTICAL ATROPHY IN ALZHEIMER DISEASE **2017**, 13, P233-P234
- 49 [P2B74]: TAU DISTRIBUTION IN PRECLINICAL ALZHEIMER'S DISEASE: FINDINGS FROM THE KNIGHT ALZHEIMER'S DISEASE RESEARCH CENTER **2017**, 13, P769-P770
- 48 [P4D44]: WHITE MATTER INTEGRITY REFLECTS TAU ACCUMULATION IN AD-DEFINED REGIONS **2017**, 13, P1370-P1371
- 47 [IC-P-054]: EXAMINING LONGITUDINAL NEUROIMAGING PATTERNS IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE: RESULTS FROM THE DOMINANTLY INHERITED ALZHEIMER NETWORK **2017**, 13, P44-P45
- 46 [IC-P-061]: APOE4 EFFECT ON LONGITUDINAL VOLUMETRICS AND PIB ACCUMULATION IN PRECLINICAL ALZHEIMER DISEASE **2017**, 13, P50-P50
- 45 [IC-P-064]: BRAIN AEROBIC GLYCOLYSIS AND AD PATHOLOGY BIOMARKERS IN AUTOSOMAL DOMINANT AD **2017**, 13, P53-P53
- 44 [IC-P-138]: CORTICAL THINNING PATTERN IN AUTOSOMAL DOMINANT AD PREDICTS AMYLOID POSITIVITY IN SPORADIC AD **2017**, 13, P105-P105
- 43 [IC-P-166]: UTILITY OF PERFUSION PET MODELS AS MEASURE OF NEURODEGENERATION IN AN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE POPULATION: REPORT FROM THE DIAN STUDY **2017**, 13, P125-P126

- 42 [IC-P-180]: FLORTAUCIPIR TAU-PET SPECIFICITY IS MAINTAINED IN PATIENTS WITH PATHOLOGICALLY CONFIRMED CREUTZFELDT-JAKOB DISEASE **2017**, 13, P134-P134
- 41 [IC-P-196]: TAU DISTRIBUTION IN PRECLINICAL ALZHEIMER'S DISEASE: FINDINGS FROM THE KNIGHT ALZHEIMER'S DISEASE RESEARCH CENTER **2017**, 13, P144-P145
- 40 [IC-P-205]: BRAIN AEROBIC GLYCOLYSIS AND TAU DEPOSITION WITH [18F]-AV-1451 PET **2017**, 13, P149-P150
- 39 [IC-0102]: WHITE MATTER INTEGRITY REFLECTS TAU ACCUMULATION IN AD-DEFINED REGIONS **2017**, 13, P1-P2
- 38 [IC-0202]: RELATIONSHIP BETWEEN TAU POSITRON EMISSION TOMOGRAPHY WITH [18F]-AV-1451 AND LONGITUDINAL CORTICAL ATROPHY IN ALZHEIMER DISEASE **2017**, 13, P4-P5
- 37 [P1B51]: THE ASSOCIATION BETWEEN PERSONALITY AND TAU PET DEPOSITION IN COGNITIVELY NORMAL OLDER ADULTS: FINDINGS FROM THE KNIGHT ALZHEIMER DISEASE RESEARCH CENTER **2017**, 13, P391-P392
- 36 [P1B02]: BRAIN AEROBIC GLYCOLYSIS AND AD PATHOLOGY BIOMARKERS IN AUTOSOMAL DOMINANT AD **2017**, 13, P427-P428
- 35 [P1B22]: RELATIONSHIP BETWEEN TAU POSITRON EMISSION TOMOGRAPHY WITH [18F]-AV-1451 AND LONGITUDINAL CORTICAL ATROPHY IN ALZHEIMER DISEASE **2017**, 13, P440-P440
- 34 [P2B45]: APOE4 EFFECT ON LONGITUDINAL VOLUMETRICS AND PIB ACCUMULATION IN PRECLINICAL ALZHEIMER DISEASE **2017**, 13, P754-P754
- 33 [O10201]: CORTICAL THINNING PATTERN IN AUTOSOMAL DOMINANT AD PREDICTS AMYLOID POSITIVITY IN SPORADIC AD **2017**, 13, P184-P185
- 32 [O10203]: EXAMINING LONGITUDINAL NEUROIMAGING PATTERNS IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE: FINDINGS FROM THE DOMINANTLY INHERITED ALZHEIMER NETWORK **2017**, 13, P186
- 31 [O20503]: CONCORDANCE BETWEEN CSF AD BIOMARKERS MEASURED BY THE AUTOMATED ELECSYS ASSAY AND IN VIVO AMYLOID IMAGING **2017**, 13, P561
- 30 [O30905]: BRAIN AEROBIC GLYCOLYSIS AND TAU DEPOSITION WITH [18F]-AV-1451 PET **2017**, 13, P922
- 29 [IC-P-197]: THE ASSOCIATION BETWEEN PERSONALITY AND TAU PET DEPOSITION IN COGNITIVELY NORMAL OLDER ADULTS: FINDINGS FROM THE KNIGHT ALZHEIMER DISEASE RESEARCH CENTER **2017**, 13, P145-P146
- 28 [O10204]: CLINICAL RISK RELATED TO CEREBRAL MICROHEMORRHAGES IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE: LONGITUDINAL RESULTS FROM THE DIAN STUDY **2017**, 13, P186-P187
- 27 IC-P-020: Comparison of nia-aa preclinical Alzheimer's disease staging with CSF and neuroimaging biomarkers **2015**, 11, P24-P25
- 26 P2-154: Patterns of tau binding in T807-PET imaging **2015**, 11, P546-P546
- 25 O2-01-03: Amyloid load increase and cerebral microbleed prevalence differ as a function of the position of the mutation within the PSEN1 coding sequence **2015**, 11, P172-P172

- 24 IC-P-117: Neuronal Injury and Degeneration Evaluated With Imaging and CSF Biomarkers in Autosomal Dominant AD: Results From The Dian Study **2016**, 12, P87-P88
- 23 P1-254: Principal Component Analysis of [18F]-Av-1451 TAU Pet in Alzheimer's Disease and Frontotemporal Dementia **2016**, 12, P507-P508
- 22 IC-P-098: Functional Connectivity with Anterior Temporal Lobe Regions Ordered According to The Braak Progression Scheme Reveals Sequential Coupling to Default Mode and Then Sensory Networks **2016**, 12, P75-P75
- 21 P3-234: Similarities and Differences in Patterns of [F18]-AV-1451 and [F18]-FDG in Frontotemporal Dementia **2016**, 12, P915-P916
- 20 P3-283: Functional Connectivity with Anterior Temporal Lobe Regions Ordered According to the Braak Progression Scheme Reveals Sequential Coupling to Default Mode and Then Sensory Networks **2016**, 12, P946-P946
- 19 IC-P-204: Principal Component Analysis of [18F]-Av-1451 TAU PET in Alzheimer's Disease and Frontotemporal Dementia **2016**, 12, P145-P146
- 18 IC-P-206: Similarities and Differences in Patterns of [F18]-Av-1451 And [F18]-FDG in Frontotemporal Dementia **2016**, 12, P147-P147
- 17 O2-08-05: Neuronal Injury and Degeneration Evaluated with Imaging and CSF Biomarkers in Autosomal Dominant Alzheimer's Disease: Results from the Dian Study **2016**, 12, P246-P246
- 16 IC-P-131: PIB BINDING TOPOGRAPHY BEST CORRELATES WITH YOUNG ADULT GLYCOLYSIS **2019**, 15, P108-P108
- 15 IC-P-094: CROSS-SECTIONAL AND LONGITUDINAL ASSOCIATION BETWEEN SERUM NEUROFILAMENT LIGHT AND ESTABLISHED WHITE MATTER NEUROIMAGING MARKERS IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE **2019**, 15, P82-P83
- 14 IC-P-098: PHOSPHORYLATION OF SPECIFIC TAU SITES IS ASSOCIATED WITH LOSS OF WHITE MATTER INTEGRITY IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE **2019**, 15, P85-P86
- 13 O3-12-01: ASSOCIATION BETWEEN SERUM NEUROFILAMENT LIGHT AND ESTABLISHED WHITE MATTER NEUROIMAGING MARKERS IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE **2019**, 15, P914-P915
- 12 Pattern and degree of individual brain atrophy predicts dementia onset in dominantly inherited Alzheimer's disease. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2021**, 13, e12197 5.2
- 11 O3-13-03: THE RELATIONSHIP BETWEEN TAU PET AND OTHER AD BIOMARKERS IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE **2018**, 14, P1056-P1057
- 10 IC-P-167: ALTERED RESTING-STATE FUNCTIONAL MRI SIGNAL ENTROPY IN TEMPORAL AND PARIETAL LOBES IN SPORADIC ALZHEIMER'S DISEASE **2018**, 14, P140-P140
- 9 IC-P-162: REGIONAL CORTICAL THINNING PATTERNS IN COGNITIVELY IMPAIRED AND CONVERTER INDIVIDUALS USING OASIS-3 DATA **2018**, 14, P136-P137
- 8 IC-P-207: EXAMINING THE ABILITY OF A TAU SPATIAL SPREAD METRIC TO INDICATE DISEASE PROGRESSION COMPARED TO AN INTENSITY-BASED APPROACH **2018**, 14, P170-P171
- 7 IC-P-009: COMPARING THE CENTILOID SCALE FOR PITTSBURGH COMPOUND B AND FLORBETAPIR IN LONGITUDINAL PET STUDIES OF SPORADIC AD **2018**, 14, P19-P19

6 IC-02-01: THE RELATIONSHIP BETWEEN TAU PET AND AGE ACROSS THE LIFESPAN **2018**, 14, P1-P2

5 IC-P-042: RESTING-STATE FUNCTIONAL CONNECTIVITY ASSOCIATES WITH PATHOLOGICAL BIOMARKERS IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE **2018**, 14, P42-P43

4 P2-362: THE RELATIONSHIP BETWEEN TAU PET AND AGE ACROSS THE LIFESPAN **2018**, 14, P829-P830

3 IC-P-043: FUNCTIONAL ARCHITECTURAL DIFFERENCES BETWEEN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE AND LATE ONSET ALZHEIMER'S DISEASE **2018**, 14, P43-P43

2 IC-04-02: SERUM NEUROFILAMENT LIGHT CHAIN LEVELS ARE ASSOCIATED WITH CORTICAL THICKNESS, BETA-AMYLOID BURDEN, AND CEREBRAL GLUCOSE METABOLISM IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE **2018**, 14, P7-P8

1 Is comprehensiveness critical? Comparing short and long format cognitive assessments in preclinical Alzheimer disease. *Alzheimer's Research and Therapy*, **2021**, 13, 153

9